• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Janssen Pharmaceuticals Inc. - Articles and news items

cost effective cancer drug

NICE says Novartis’ and Janssen’s cancer drugs are not cost effective

Industry news / 18 August 2016 / The National Institute for Health and Care Excellence (NICE)

New draft guidance advises that everolimus, for treating advanced breast cancer after endocrine therapy, and ibrutinib, for treating relapsed or refractory mantle cell lymphoma, be removed from the Cancer Drugs Fund for not being cost effective…

chewable mebendazole

FDA grants priority review to Janssen’s chewable mebendazole

Industry news / 14 July 2016 / Victoria White, Digital Content Producer

If approved, chewable mebendazole will provide a treatment and prevention alternative for adults and children with soil-transmitted helminthiasis…

ebola-vaccine

Positive Phase I results for preventive Ebola vaccine regimen

Industry news / 20 April 2016 / Victoria White, Digital Content Producer

Data from a Phase I study of a preventive Ebola vaccine regimen suggest that the regimen was well-tolerated by healthy volunteers and immunogenic…

DPP-4 inhibitors

First real-world evidence comparing an SGLT2 inhibitor with DPP-4 inhibitors

Industry news / 15 March 2016 / Victoria White

A real-world study showed use of Invokana (canagliflozin) is associated with significantly greater improvements in blood glucose control compared to DPP-4 inhibitors…

psoriasis

Janssen reveals the psychological impact of psoriasis

Industry news / 14 October 2015 / Victoria White

Janssen’s EPIDEPSO study was initiated to better understand the correlation between psychosocial comorbidities and psoriasis…

ebola-MVA-BN-Filo

Oxford Vaccine Group initiates Phase 2 study of Ebola prime-boost vaccine regimen combining MVA-BN-Filo and Ad26.ZEBOV

Industry news / 15 July 2015 / Victoria White

Oxford Vaccine Group has initiated a Phase 2 clinical study of the Ebola prime-boost vaccine regimen that combines MVA-BN-Filo with Ad26.ZEBOV…

eular

Janssen to present 17 abstracts in ankylosing spondylitis, rheumatoid arthritis, psoriatic arthritis and psoriasis at EULAR

Industry news / 11 June 2015 / Victoria White

Seventeen Janssen Immunology abstracts in ankylosing spondylitis, rheumatoid arthritis, psoriatic arthritis and psoriasis, will be presented at EULAR…

blood-clots

New clinical research programme launched for the prevention and treatment of blood clots in patients with cancer

Industry news / 29 May 2015 / VIctoria White

Janssen and Bayer have launched a clinical research programme evaluating rivaroxaban for the prevention and treatment of blood clots in patients with cancer…

stelara

FDA approves Invega Trinza four-times-a-year treatment for schizophrenia

Industry news / 20 May 2015 / Victoria White

The FDA have approved Janssen’s New Drug Application (NDA) for the three-month long-acting atypical antipsychotic Invega Trinza…

compassionate-use-johnson

Johnson & Johnson announces groundbreaking partnership to evaluate compassionate use requests of investigational medicines

Industry news / 7 May 2015 / Victoria White

J&J has announced a first-of-its-kind partnership that enlists a third party to review compassionate use requests made for investigational medicines…

european-health-parliament

EU’s next-gen ‘healthcare heroes’ to forge ahead at European Health Parliament

Industry news / 24 April 2015 / Victoria White

Young healthcare enthusiasts involved in the European Health Parliament will meet on Friday to push ahead with their ideas on Europe’s future healthcare…

simeprevir

Janssen announces results for its hepatitis C treatment simeprevir

Industry news / 24 April 2015 / Victoria White

Janssen Sciences Ireland UC announced results for its hepatitis C treatment simeprevir at The International Liver Congress™ 2015…

 

Webinar: Different thermal analysis techniques to measure the glass transitionWATCH NOW
+ +